NASDAQ:AVRO - Avrobio Stock Price, Forecast & News

Avrobio trades on the NASDAQ under the ticker symbol "AVRO."

Avrobio Inc (NASDAQ:AVRO) announced its earnings results on Thursday, November, 7th. The company reported ($0.57) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.59) by $0.02. View Avrobio's Earnings History.

Avrobio is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for Avrobio.

6 brokers have issued 1-year price objectives for Avrobio's stock. Their forecasts range from $24.42 to $43.00. On average, they anticipate Avrobio's share price to reach $33.08 in the next year. This suggests a possible upside of 45.2% from the stock's current price. View Analyst Price Targets for Avrobio.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avrobio in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avrobio.

News coverage about AVRO stock has been trending somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Avrobio earned a news impact score of -1.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Avrobio.

Avrobio saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 1,610,000 shares, a decline of 8.5% from the December 15th total of 1,760,000 shares. Based on an average daily volume of 189,600 shares, the short-interest ratio is presently 8.5 days. Currently, 7.2% of the shares of the stock are sold short. View Avrobio's Current Options Chain.

Some companies that are related to Avrobio include Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Regenxbio (RGNX), Cortexyme (CRTX), Editas Medicine (EDIT), SpringWorks Therapeutics (SWTX), Orchard Therapeutics (ORTX), Coherus Biosciences (CHRS), Alector (ALEC), DBV TECHNOLOGIE/S (DBVT), Aerie Pharmaceuticals (AERI), NanoString Technologies (NSTG), Sangamo Therapeutics (SGMO), Krystal Biotech (KRYS) and BAVARIAN NORDIC/S (BVNRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Avrobio investors own include Exelixis (EXEL), Biohaven Pharmaceutical (BHVN), Aerie Pharmaceuticals (AERI), Arrowhead Pharmaceuticals (ARWR), Axsome Therapeutics (AXSM), Cronos Group (CRON), Dicerna Pharmaceuticals (DRNA), Fate Therapeutics (FATE), Amicus Therapeutics (FOLD) and Uniqure (QURE).

(AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.

Avrobio's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Nisa Investment Advisors LLC (0.08%). Company insiders that own Avrobio stock include Bruce Booth, Christopher Paige and Geoffrey Mackay. View Institutional Ownership Trends for Avrobio.

AVRO stock was bought by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC. View Insider Buying and Selling for Avrobio.

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AVRO stock can currently be purchased for approximately $22.78.

Avrobio has a market capitalization of $721.44 million. The company earns $-46,360,000.00 in net income (profit) each year or ($3.62) on an earnings per share basis. Avrobio employs 49 workers across the globe.View Additional Information About Avrobio.

The official website for Avrobio is http://www.avrobio.com/.

Avrobio's mailing address is ONE KENDALL SQUARE BLDG. 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-914-8420 or via email at [email protected]